What are the best treatments for Amyotrophic lateral sclerosis ALS?

Treatment for Amyotrophic lateral sclerosis (ALS) focuses on slowing disease progression, managing symptoms, and maintaining quality of life through a multidisciplinary approach. While there is no cure, FDA-approved medications like riluzole and edaravone are considered first-line therapies, often paired with comprehensive supportive care to address respiratory, nutritional, and mobility needs.

What are the primary medications for Amyotrophic lateral sclerosis (ALS)?

Management of Amyotrophic lateral sclerosis (ALS) typically begins with disease-modifying therapies approved to extend survival or preserve function. Riluzole (Rilutek) was the first medication approved for this condition and works by modulating glutamate levels, a neurotransmitter often overactive in patients. Edaravone (Radicava), administered via intravenous infusion or oral suspension, acts as an antioxidant to reduce oxidative stress on motor neurons. More recently, tofersen (Qalsody) has been approved specifically for patients with Amyotrophic lateral sclerosis (ALS) associated with a mutation in the SOD1 gene. It is critical to note that medication efficacy varies significantly between individuals; dosages and therapeutic regimens must be strictly personalized by a neurologist.

What supportive and non-pharmacological treatments are available?

Because Amyotrophic lateral sclerosis (ALS) affects motor function, non-pharmacological interventions are essential for maintaining independence and comfort. Supportive care is often as important as medical therapy. Key interventions include:

• Respiratory Support: Non-invasive ventilation (NIV), such as BiPAP, is often introduced early to assist with breathing and improve sleep quality.


• Nutritional Management: A gastrostomy (G-tube) is frequently recommended when swallowing becomes difficult to ensure adequate caloric intake and hydration.


• Physical and Occupational Therapy: These therapies focus on energy conservation techniques, maintaining range of motion, and utilizing assistive devices like orthotics or wheelchairs.


• Speech Therapy: Specialists work with patients on communication strategies, including the use of augmentative and alternative communication (AAC) devices as voice function declines.

Which specialists should be on the care team?

The most effective care for Amyotrophic lateral sclerosis (ALS) is delivered through a multidisciplinary clinic. This team-based model ensures that all aspects of the disease are addressed simultaneously. A comprehensive care team should include a neurologist specializing in neuromuscular disorders, a pulmonologist, a physical therapist, an occupational therapist, a speech-language pathologist, a registered dietitian, and a social worker or clinical psychologist. Members of the DiseaseMaps.org community, which includes 333 people living with this condition, often report that coordinating care through a dedicated ALS center significantly reduces the burden of managing complex symptoms.

What does the future hold for Amyotrophic lateral sclerosis (ALS) research?

The landscape for Amyotrophic lateral sclerosis (ALS) research is rapidly evolving, with dozens of clinical trials currently investigating gene therapies, neuroprotective agents, and stem cell-based approaches. Researchers are increasingly focusing on precision medicine, identifying specific genetic markers to tailor treatments to the individual patient’s biological profile. Participation in clinical trials is a vital pathway for many families seeking access to emerging therapies while contributing to the global scientific understanding of the disease.

Next steps

• Consult a board-certified neuromuscular neurologist to discuss current treatment eligibility.


• Request a referral to a multidisciplinary ALS clinic for comprehensive care coordination.


• Connect with the 333 members of the DiseaseMaps.org community to share experiences and coping strategies.


• Review active clinical trials on ClinicalTrials.gov to see if you or a loved one meets the inclusion criteria for new research.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult with your healthcare provider for diagnosis and treatment decisions specific to your health needs.

References

• National Institute of Neurological Disorders and Stroke (NINDS): ALS Information Page


• Orphanet: Amyotrophic lateral sclerosis (ORPHA:803)


• The ALS Association: Understanding ALS Treatments


• NIH Genetic and Rare Diseases Information Center (GARD): Amyotrophic lateral sclerosis